Engineering Protease-Resistant Peptides for Better Drug Targeting and Delivery
Review of chemical strategies to make peptides resistant to enzymatic degradation while maintaining their targeting and intracellular delivery capabilities for next-generation therapeutics.
Quick Facts
What This Study Found
Comprehensive review of strategies to enhance peptide proteolytic resistance for targeting and intracellular delivery: D-amino acids, cyclization, PEGylation, unnatural amino acids, backbone modifications, and hybrid approaches.
Key Numbers
Strategies: N/C-cap, cyclization, backbone mod, D-amino acids, conjugation; best for brain delivery: retro-enantio
How They Did This
Narrative review of chemical modification strategies for protease-resistant peptide design in drug delivery applications.
Why This Research Matters
Proteolytic degradation is the single biggest barrier to peptide therapeutics. A comprehensive understanding of stabilization strategies enables rational design of peptide drugs that survive in the body.
The Bigger Picture
As peptide drugs grow from niche to mainstream therapeutics, protease resistance engineering becomes a standard pharmaceutical discipline. This review provides the design toolkit.
What This Study Doesn't Tell Us
Review article. Different strategies suit different peptide applications. Some modifications may reduce biological activity. Manufacturing complexity varies widely.
Questions This Raises
- ?Which stabilization strategy best preserves cell-penetrating activity?
- ?Can AI predict optimal combinations of modifications for specific peptide drugs?
- ?What are the cost implications of each approach for pharmaceutical manufacturing?
Trust & Context
- Key Stat:
- Stability toolkit Multiple chemical strategies — D-amino acids, cyclization, PEGylation, backbone modifications — each address peptide instability with different trade-offs for drug development
- Evidence Grade:
- Not applicable (review article).
- Study Age:
- Published 2021.
- Original Title:
- Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics.
- Published In:
- Pharmaceutics, 13(12) (2021)
- Authors:
- Lucana, Maria C, Arruga, Yolanda, Petrachi, Emilia, Roig, Albert, Lucchi, Roberta, Oller-Salvia, Benjamí
- Database ID:
- RPEP-05568
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why do peptide drugs break down so fast?
The body contains thousands of proteases — enzymes whose job is to break down proteins and peptides. Therapeutic peptides are seen as food by these enzymes. Chemical modifications can disguise or protect peptides from this degradation.
Which modification works best?
It depends on the peptide and application. Cyclization works well for oral delivery, D-amino acids for enzyme resistance, PEGylation for extending half-life. Often, combining multiple strategies provides the best result.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05568APA
Lucana, Maria C; Arruga, Yolanda; Petrachi, Emilia; Roig, Albert; Lucchi, Roberta; Oller-Salvia, Benjamí. (2021). Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics.. Pharmaceutics, 13(12). https://doi.org/10.3390/pharmaceutics13122065
MLA
Lucana, Maria C, et al. "Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics.." Pharmaceutics, 2021. https://doi.org/10.3390/pharmaceutics13122065
RethinkPeptides
RethinkPeptides Research Database. "Protease-Resistant Peptides for Targeting and Intracellular ..." RPEP-05568. Retrieved from https://rethinkpeptides.com/research/lucana-2021-proteaseresistant-peptides-for-targeting
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.